Company profile

Nimbus Saturn, Inc.

Privately held: no public share price (Program subsidiary holding Nimbus's HPK1/MAP4K1 inhibitor; Nimbus Therapeutics is privately held and no divestiture or listing was found for Saturn. Parent: Nimbus Therapeutics LLC (private). [resolved 2026-08-05 by resolve-null-is-public; source: https://patents.justia.com/assignee/nimbus-saturn-inc]) · United States

Assets

(1 total)

1Total Assets

0Approved

0Phase 3 / Filed

1Phase 1–2 / Early

1Diseases

Showing 1 of 1 assets

		Target & Modality
NDI-101150	Phase 2	HPK1 / MAP4K1 (hematopoietic progenitor kinase 1)Small molecule	Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.